3.30Open3.30Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover0.00%IV5.65%PremiumDec 20, 2024Expiry Date3.07Intrinsic Value100Multiplier27DDays to Expiry0.23Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.36Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet